• Careers
  • Contact
Intensity Therapeutics
Intensity Therapeutics
  • Home
  • Company
    • Introduction
    • Senior Management Team
    • Board of Directors
    • Scientific Advisors
  • Clinical Research
    • Overview
    • FAQs
    • For Patients
  • Technology
    • DfuseRx℠ Product Discovery Technology
    • Pipeline
    • Lead Product: INT230-6
    • Mechanism of Action
    • Intellectual Property and Patents
  • Partnerships
  • News & Events
    • Press Releases
    • Events and Presentations
    • Intensity Therapeutics in the News
    • Publications, Papers and Posters
  • Investors
Intensity Therapeutics
  • Home
  • Company
    • Introduction
    • Senior Management Team
    • Board of Directors
    • Scientific Advisors
  • Clinical Research
    • Overview
    • FAQs
    • For Patients
  • Technology
    • DfuseRx℠ Product Discovery Technology
    • Pipeline
    • Lead Product: INT230-6
    • Mechanism of Action
    • Intellectual Property and Patents
  • Partnerships
  • News & Events
    • Press Releases
    • Events and Presentations
    • Intensity Therapeutics in the News
    • Publications, Papers and Posters
  • Investors
  • Careers
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financials
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Events & Presentations
  • Email Alerts
May 06, 2025 8:00am EDT

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025 8:00am EDT

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Mar 13, 2025 4:07pm EDT

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Jan 28, 2025 8:00am EST

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025 8:00am EST

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 12, 2024 8:00am EST

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024 8:00am EST

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024 8:00am EST

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024 4:06pm EST

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 08, 2024 8:01am EST

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • Privacy Policy
Menu
  • Privacy Policy

© 2025 Intensity Therapeutics. All rights reserved.

Linkedin Twitter